Proscia Receives New FDA 510(k) Clearance for Concentriq AP-Dx with Predetermined Change Control Plan
recent articles
Roche: Information platform empowers the public with knowledge on latest cancer treatment technologies According to data from the Hong Kong Cancer Registry of the Hospital Authority, the overall five-year survival rate for cancer patients has...
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody,...
Artera: Clinicians and patients throughout New York State can now access personalized, actionable insights to inform prostate cancer treatment decisions SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal...
Proscia: Survey of 360 senior professionals finds modernization is key to overcoming longstanding industry challenges PHILADELPHIA — June 11, 2025 — Diagnostic laboratory leaders view digital pathology and artificial intelligence (AI)...
Paige and Breast International Group (BIG): The global partnership will leverage Paige’s technology to reduce unnecessary treatment, support better patient stratification, and help standardize the measurement of residual cancer...
Join Aiforia for their webinar on AI in lung cancer pathology PD-L1 on the edge: cut-offs, cognitive bias & the case for AI in lung cancer pathology Date: Monday, June 23, 2025 Time: 3:00 p.m. CEST / 9:00 a.m. EDT Register to join live...
